tiprankstipranks
Nuvation Bio Inc (NUVB)
NYSE:NUVB
US Market
NUVB
Nuvation Bio
RESEARCH TOOLSreports
Want to see NUVB full AI Analyst Report?

Nuvation Bio (NUVB) Stock Forecast & Price Target

806 Followers
See the Price Targets and Ratings of:

NUVB Analyst Ratings

Strong Buy
7Ratings
Strong Buy
6 Buy
1 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Nuvation
Bio
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NUVB Stock 12 Month Forecast

Average Price Target

$13.17
▲(159.19% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Nuvation Bio in the last 3 months. The average price target is $13.17 with a high forecast of $20.00 and a low forecast of $7.00. The average price target represents a 159.19% change from the last price of $5.08.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","21":"$21","5.25":"$5.25","10.5":"$10.5","15.75":"$15.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.166666666666668,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5.25,10.5,15.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.49,5.683076923076923,6.876153846153846,8.06923076923077,9.262307692307694,10.455384615384617,11.64846153846154,12.841538461538462,14.034615384615385,15.227692307692308,16.42076923076923,17.613846153846154,18.806923076923077,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.49,5.157435897435898,5.824871794871795,6.492307692307692,7.15974358974359,7.827179487179487,8.494615384615386,9.162051282051284,9.829487179487181,10.496923076923078,11.164358974358976,11.831794871794873,12.49923076923077,{"y":13.166666666666668,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.49,4.683076923076923,4.876153846153846,5.069230769230769,5.262307692307693,5.455384615384616,5.648461538461539,5.841538461538462,6.0346153846153845,6.227692307692308,6.420769230769231,6.613846153846154,6.806923076923077,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.27,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.88,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.96,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.84,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.51,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.49,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$20.00Average Price Target$13.17Lowest Price Target$7.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on NUVB
Robert Burns
H.C. Wainwright
H.C. Wainwright
$17
Buy
234.65%
Upside
Reiterated
05/07/26
Analyst Reiterates Buy on Nuvation Bio, Maintains $17 Price Target on Long-Term IBTROZI Growth Potential
JonesTrading Analyst forecast on NUVB
Boris Peaker
JonesTrading
JonesTrading
$10→$12
Buy
136.22%
Upside
Reiterated
05/05/26
Analysts Conflicted on These Healthcare Names: Fortrea Holdings Inc. (NASDAQ: FTRE), Vertex Pharmaceuticals (NASDAQ: VRTX) and Nuvation Bio (NYSE: NUVB)
Wedbush Analyst forecast on NUVB
David Nierengarten
Wedbush
Wedbush
$11
Buy
116.54%
Upside
Reiterated
05/05/26
Wedbush Keeps Their Buy Rating on Nuvation Bio (NUVB)
Truist Financial Analyst forecast on NUVB
Gregory Renza
Truist Financial
Truist Financial
$12
Buy
136.22%
Upside
Reiterated
05/05/26
Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Evolus (EOLS)
TD Cowen Analyst forecast on NUVB
Yaron Werber
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/04/26
Yaron Werber Reiterates Buy on Ibtrozi Maker, Citing Growing First‑Line Adoption and Market Share Gains in ROS1‑Positive Lung Cancer Despite Near‑Term Estimate Cuts
RBC Capital Analyst forecast on NUVB
Leonid Timashev
RBC Capital
RBC Capital
$20
Buy
293.70%
Upside
Reiterated
05/04/26
Analysts Offer Insights on Healthcare Companies: ADC Therapeutics (NYSE: ADCT), Evolus (NASDAQ: EOLS) and Nuvation Bio (NYSE: NUVB)
UBS Analyst forecast on NUVB
Michael Yee
UBS
UBS
$10→$7
Hold
37.80%
Upside
Reiterated
03/03/26
Nuvation Bio price target lowered to $7 from $10 at UBSNuvation Bio price target lowered to $7 from $10 at UBS
B. Riley Securities Analyst forecast on NUVB
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$12
Buy
136.22%
Upside
Reiterated
01/13/26
Nuvation Bio shares attractive on weakness, says B. RileyNuvation Bio shares attractive on weakness, says B. Riley
Clear Street Analyst forecast on NUVB
Kaveri Pohlman
Clear Street
Clear Street
$12
Buy
136.22%
Upside
Reiterated
11/26/25
Clear Street says thesis intact after Nuvation's NUV-1511 discontinuedClear Street says thesis intact after Nuvation's NUV-1511 discontinued
Citizens JMP Analyst forecast on NUVB
Silvan Tuerkcan
Citizens JMP
Citizens JMP
$8→$10
Buy
96.85%
Upside
Reiterated
11/20/25
Nuvation Bio price target raised to $10 from $8 at Citizens JMPNuvation Bio price target raised to $10 from $8 at Citizens JMP
Jefferies Analyst forecast on NUVB
Farzin Haque
Jefferies
Jefferies
$10
Buy
96.85%
Upside
Initiated
09/29/25
Nuvation Bio's Strategic Growth Potential and Promising Pipeline Justify Buy Rating
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on NUVB
Robert Burns
H.C. Wainwright
H.C. Wainwright
$17
Buy
234.65%
Upside
Reiterated
05/07/26
Analyst Reiterates Buy on Nuvation Bio, Maintains $17 Price Target on Long-Term IBTROZI Growth Potential
JonesTrading Analyst forecast on NUVB
Boris Peaker
JonesTrading
JonesTrading
$10→$12
Buy
136.22%
Upside
Reiterated
05/05/26
Analysts Conflicted on These Healthcare Names: Fortrea Holdings Inc. (NASDAQ: FTRE), Vertex Pharmaceuticals (NASDAQ: VRTX) and Nuvation Bio (NYSE: NUVB)
Wedbush Analyst forecast on NUVB
David Nierengarten
Wedbush
Wedbush
$11
Buy
116.54%
Upside
Reiterated
05/05/26
Wedbush Keeps Their Buy Rating on Nuvation Bio (NUVB)
Truist Financial Analyst forecast on NUVB
Gregory Renza
Truist Financial
Truist Financial
$12
Buy
136.22%
Upside
Reiterated
05/05/26
Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Evolus (EOLS)
TD Cowen Analyst forecast on NUVB
Yaron Werber
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/04/26
Yaron Werber Reiterates Buy on Ibtrozi Maker, Citing Growing First‑Line Adoption and Market Share Gains in ROS1‑Positive Lung Cancer Despite Near‑Term Estimate Cuts
RBC Capital Analyst forecast on NUVB
Leonid Timashev
RBC Capital
RBC Capital
$20
Buy
293.70%
Upside
Reiterated
05/04/26
Analysts Offer Insights on Healthcare Companies: ADC Therapeutics (NYSE: ADCT), Evolus (NASDAQ: EOLS) and Nuvation Bio (NYSE: NUVB)
UBS Analyst forecast on NUVB
Michael Yee
UBS
UBS
$10→$7
Hold
37.80%
Upside
Reiterated
03/03/26
Nuvation Bio price target lowered to $7 from $10 at UBSNuvation Bio price target lowered to $7 from $10 at UBS
B. Riley Securities Analyst forecast on NUVB
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$12
Buy
136.22%
Upside
Reiterated
01/13/26
Nuvation Bio shares attractive on weakness, says B. RileyNuvation Bio shares attractive on weakness, says B. Riley
Clear Street Analyst forecast on NUVB
Kaveri Pohlman
Clear Street
Clear Street
$12
Buy
136.22%
Upside
Reiterated
11/26/25
Clear Street says thesis intact after Nuvation's NUV-1511 discontinuedClear Street says thesis intact after Nuvation's NUV-1511 discontinued
Citizens JMP Analyst forecast on NUVB
Silvan Tuerkcan
Citizens JMP
Citizens JMP
$8→$10
Buy
96.85%
Upside
Reiterated
11/20/25
Nuvation Bio price target raised to $10 from $8 at Citizens JMPNuvation Bio price target raised to $10 from $8 at Citizens JMP
Jefferies Analyst forecast on NUVB
Farzin Haque
Jefferies
Jefferies
$10
Buy
96.85%
Upside
Initiated
09/29/25
Nuvation Bio's Strategic Growth Potential and Promising Pipeline Justify Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nuvation Bio

3 Months
Yaron WerberTD Cowen
Success Rate
8/15 ratings generated profit
53%
Average Return
+7.85%
Copying Yaron Werber's trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of +7.85% per trade.
1 Year
David NierengartenWedbush
Success Rate
12/21 ratings generated profit
57%
Average Return
+40.36%
Copying David Nierengarten's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +40.36% per trade.
2 Years
Gregory RenzaTruist Financial
Success Rate
14/20 ratings generated profit
70%
Average Return
+52.34%
Copying Gregory Renza's trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +52.34% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NUVB Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
15
10
17
16
20
Buy
11
4
3
1
2
Hold
1
1
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
15
22
18
23
In the current month, NUVB has received 22 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. NUVB average Analyst price target in the past 3 months is 13.17.
Each month's total comprises the sum of three months' worth of ratings.

NUVB Financial Forecast

NUVB Earnings Forecast

Next quarter’s earnings estimate for NUVB is -$0.15 with a range of -$0.16 to -$0.13. The previous quarter’s EPS was $0.01. NUVB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NUVB has Performed in-line its overall industry.
Next quarter’s earnings estimate for NUVB is -$0.15 with a range of -$0.16 to -$0.13. The previous quarter’s EPS was $0.01. NUVB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NUVB has Performed in-line its overall industry.

NUVB Sales Forecast

Next quarter’s sales forecast for NUVB is $28.03M with a range of $22.00M to $36.62M. The previous quarter’s sales results were $83.23M. NUVB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NUVB has Performed in-line its overall industry.
Next quarter’s sales forecast for NUVB is $28.03M with a range of $22.00M to $36.62M. The previous quarter’s sales results were $83.23M. NUVB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NUVB has Performed in-line its overall industry.

NUVB Stock Forecast FAQ

What is NUVB’s average 12-month price target, according to analysts?
Based on analyst ratings, Nuvation Bio Inc’s 12-month average price target is 13.17.
    What is NUVB’s upside potential, based on the analysts’ average price target?
    Nuvation Bio Inc has 159.19% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NUVB a Buy, Sell or Hold?
          Nuvation Bio Inc has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Nuvation Bio Inc’s price target?
            The average price target for Nuvation Bio Inc is 13.17. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $20.00 ,the lowest forecast is $7.00. The average price target represents 159.19% Increase from the current price of $5.08.
              What do analysts say about Nuvation Bio Inc?
              Nuvation Bio Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of NUVB?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.